Equities Analysts Issue Forecasts for BCRX Q1 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Wedbush raised their Q1 2026 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, June 30th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $0.18 per share for the quarter, up from their prior forecast of $0.11. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2026 earnings at $0.25 EPS, FY2027 earnings at $0.79 EPS and FY2029 earnings at $1.07 EPS.

Several other research firms have also issued reports on BCRX. JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, June 25th. Bank of America raised their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Stock Down 0.8%

Shares of BioCryst Pharmaceuticals stock traded down $0.08 during trading on Wednesday, reaching $8.95. The company's stock had a trading volume of 1,407,127 shares, compared to its average volume of 3,032,538. BioCryst Pharmaceuticals has a 52-week low of $6.02 and a 52-week high of $11.31. The firm's 50-day moving average is $10.04 and its two-hundred day moving average is $8.59. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -34.40, a PEG ratio of 2.58 and a beta of 1.04.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $32,000. GF Fund Management CO. LTD. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $33,000. GAMMA Investing LLC boosted its holdings in BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC bought a new stake in BioCryst Pharmaceuticals in the first quarter valued at $62,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter valued at $79,000. Institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.